Clinical Trial Update: Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating two doses of Tiotropium Respimat versus placebo in adolescents with severe persistent asthma reported efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tiotropium Respimat (tiotropium)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2014-10-20